Related Experiment Videos
[Inhaled nitric oxide in anesthesia and intensive care]
C Girard1, O Bastien, S Estanove
1Département d'anesthésie-réanimation, hôpital du Bocage, Dijon, France.
Annales Francaises D'Anesthesie Et De Reanimation
|January 1, 1997
Summary
Inhaled nitric oxide (NO) selectively dilates pulmonary arteries, treating pulmonary artery hypertension and improving oxygenation in conditions like ARDS and neonatal hypoxemia. Careful administration minimizes toxicity risks.
Area of Science:
- Cardiovascular Physiology
- Pulmonary Medicine
- Medical Therapeutics
Background:
- Endothelium-derived relaxing factors (EDRFs) mediate vascular relaxation, with nitric oxide (NO) identified in 1987.
- Nitric oxide (NO) plays diverse physiological and pathophysiological roles.
- Atmospheric NO is a pollutant, yet inhaled NO has therapeutic applications.
Purpose of the Study:
- To review the therapeutic applications of inhaled nitric oxide (NO).
- To discuss the mechanism of selective pulmonary vasodilation by inhaled NO.
- To evaluate the benefits and risks of inhaled NO in various clinical conditions.
Main Methods:
- Review of existing literature on inhaled nitric oxide (NO) therapy.
- Analysis of NO's mechanism of action in pulmonary circulation.
- Examination of clinical data from studies involving NO in pulmonary artery hypertension (PAH), ARDS, and neonatal hypoxemia.
Main Results:
- Inhaled NO causes selective pulmonary vasodilation, beneficial for pulmonary artery hypertension (PAH) and right ventricular failure post-surgery.
- In acute respiratory distress syndrome (ARDS), inhaled NO improves pulmonary perfusion and oxygenation.
- In neonates, inhaled NO can alleviate refractory hypoxemia, though bronchodilatory effects are limited in obstructive lung disease.
Conclusions:
- Inhaled NO is a valuable treatment for specific conditions like PAH and ARDS, offering selective pulmonary vasodilation.
- Careful administration and monitoring are crucial to manage potential toxicity from NO and its metabolite NO2.
- Long-term benefits in ARDS require further multicenter controlled studies, but risks appear low compared to therapeutic advantages in selected patients.